EREBRAL vasospasm after subarachnoid hemorrhage (SAH) is a serious complication that occurs following the rupture of intracranial aneurysms.
Another goal of this study is to evaluate the role of second messenger systems in the functional modification of CGRP vasoactivity. Cyclic nucleotide second messengers play a prominent role in regulating cerebrovascular tone. 5 Moreover, both cyclic 3Ј,5Ј-adenosine monophosphate (cAMP) and cyclic 3Ј,5Ј-guanosine monophosphate (cGMP) have been implicated as mediators of the vasodilatory responses to CGRP. 14, 24 It is plausible that alterations in one or both of these systems could underlie the modification in CGRP-induced dilation observed during cerebral vasospasm. The present study evaluates this issue.
Materials and Methods

Rabbit Model of Subarachnoid Hemorrhage
New Zealand White male rabbits, weighing 2.8 to 3.5 kg, were anesthetized by intramuscular injection of ketamine (25 mg/kg) and xylazine (2.5 mg/kg). Subarachnoid hemorrhage was induced in 72 rabbits (SAH group) as described in detail elsewhere 17 and an additional 72 animals were used for the control (non-SAH) groups. Briefly, 2.5 ml of fresh, autologous, nonheparinized arterial blood withdrawn from the central ear artery was injected percutaneously into the cisterna magna of the animals in the SAH group over a 10-second period. The animals were monitored during postsurgical recovery and then returned to the vivarium.
Preparation of the Basilar Artery and Tension Recording
Two days after blood injection the SAH animals were sacrificed and ring strips of the basilar artery were prepared as follows. The rabbits were anesthetized by intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg), after which they were orally intubated, paralyzed with an intravenous injection of pancuronium bromide (0.08 mg/kg), and ventilated using a dual-phase control respirator. While the heart was still beating, each animal was perfused intracardially with 100 ml of aerated (95% O 2 /5% CO 2 ) modified Krebs' solution (in mM: NaCl, 120; KCl, 4.5; MgSO 4 , 1.0; NaHCO 3 , 27.0; KH 2 PO 4 , 1.0; CaCl 2 , 2.5; and dextrose, 10.0) at room temperature. Exsanguination was achieved by severing both femoral arteries. The basilar arteries were dissected free with the aid of a stereomicroscope after the brainstem was removed en bloc. Four basilar arterial rings, each 3 mm in length, were obtained from each animal and prepared according to established methods. 6 Each ring was suspended between two L-shaped, silicon-coated rods in an organ bath with a 10-ml working volume and placed in an isometric tension setup. Isometric tension was recorded using a force-displacement transducer, a polygraph, and a chart recorder. The resting tension was adjusted to 400 mg and the preparations were allowed to equilibrate at 37˚C for 1 hour prior to any drug treatment. Similar preparative steps were undertaken for vessels from non-SAH animals. All vessels were tested initially for their responses to treatment with 40 mM KCl. If consistent contractions were ob-served in two consecutive treatments with elevated KCl, the vessels were used for drug testing.
Drug Preparation and Treatment
Nitroglycerin (GTN) was obtained at a concentration of 5 mg/ml. Stock solutions of forskolin were made by dissolving the drug in dimethyl sulfoxide. The CGRP was dissolved in double-distilled water. The drugs were further diluted in modified Kreb's solution before use and the final volume of a given drug-containing solution was less than 0.2 ml. Drugs were added directly to the 10-ml organ baths. In experiments in which multiple concentrations of a single drug were tested, the compound was added to the bath in a cumulative manner.
Assays for cAMP and cGMP
Calcitonin gene-related peptide (1, 10, and 100 nM), forskolin (1, 10, and 100 nM), or GTN (0.1 and 10 M) was added for 3 minutes to the organ bath after the arterial strips had been equilibrated for 1 hour at 37˚C. The reaction was halted by soaking the arterial strips in ice-cold acidic ethanol (1 ml 1 N HCl:100 ml ethanol). The strips were then homogenized in the same solution using a glass homogenizer. The homogenate was centrifuged and the pellet was used for the assay of protein levels after air drying. 1 The supernatant was dried by heating it to 50˚C under a stream of air. Samples were assayed for cAMP or cGMP using standardized enzyme immunoassay kits. Absorbance at wavelengths of 405 nm for cAMP and 450 nm for cGMP was determined using an automated microplate reader.
Supplies and Equipment
The dual-phase control respirator, model 683, was obtained from Harvard Instruments, South Natick, Massachusetts. The forcedisplacement transducer, model FT03D, and the polygraph, model 79D, were supplied by Grass Instruments, Quincy, Massachusetts. Soltec Corporation, Sun Valley, California, provided the chart recorder model 3418. The automated microplate reader, model EL311SX, was obtained from Bio-Tek Instruments, Winooski, Vermont.
Nitrogycerin was supplied by Solo Pak Laboratories, Inc., Elk Grove Village, Illinois. All other drugs used in the experiment were obtained from Sigma Chemical Company, St. Louis, Missouri. Assays for cAMP and cGMP were performed using enzyme immunoassay kits provided by Cayman Chemicals Ann Arbor, Michigan, and Amersham Corporation, Arlington Heights, Illinois, respectively.
Statistical Analysis
The values presented in this study are expressed as means Ϯ the standard error of the means. Differences between means within each experiment were evaluated by analysis of variance. If significant differences were demonstrated, the two-tailed Student's unpaired ttest was used to determine which pairs of means were significantly different. Probability values less than 0.05 were considered significant.
Results
Tension Measurement Studies
In these studies we examined changes in the isometric tension of ring strips of rabbit basilar arteries in response to treatment with signaling molecules. We then compared responses in vessels prepared from non-SAH and SAH animals.
Effects of SAH on Contractions Induced by Potassium or
Serotonin. The treatment of ring strips of basilar arteries with a high concentration of KCl (40 mM) provoked contractions with peak values of 1.94 Ϯ 0.48 g (seven arterial ring strips) and 1.45 Ϯ 0.40 g (five arterial ring strips) in vessels from non-SAH and SAH rabbits, respectively. Although the magnitude of contractions in response to KCl was lower in vessels from SAH animals, this effect did not achieve statistical significance.
The maximum contraction elicited by serotonin (5-HT) was markedly augmented in vessels from SAH rabbits (Fig. 1) . The sensitivity of the vessels to 5-HT was also enhanced as indicated by the shift to the left in the doseresponse curve for the SAH vessels ( Fig. 1) . Mean effective concentration (EC 50 ) values for 5-HT were 0.41 Ϯ 0.16 M (seven arterial ring strips) and 0.017 Ϯ 0.004 M (five arterial ring strips) in vessels from non-SAH and SAH rabbits, respectively; this difference was statistically significant (p Ͻ 0.05).
Effects of SAH on Vasorelaxation Induced by CGRP.
The vasorelaxant effects of CGRP were tested by applying doses of the peptide in a cumulative fashion to vessels precontracted with 5-HT. To achieve similar plateau levels of precontraction, vessels from non-SAH rabbits were treated with 10 M 5-HT, whereas vessels from SAH animals were treated with 0.3 M 5-HT. Calcitonin gene-related peptide (0.1-100 nM) reversed 5-HT-induced contraction in a concentration-dependent manner in vascular strips obtained from both non-SAH and SAH rabbits. However, the relaxing effect of CGRP was shown to be attenuated after SAH. The concentration-response curve was significantly shifted to the right in strips obtained from SAH rabbits (Fig. 2 left) .
Effects of SAH on Vasorelaxation Induced by Forskolin and GTN.
Vasorelaxation responses to activators of cyclic nucleotides were tested as described above. Forskolin (0.1-100 nM), an activator of adenylate cyclase, 21 elicited concentration-dependent relaxation in strips precontracted with 5-HT. At concentrations of 10 and 30 nM, forskolininduced vasorelaxation was significantly greater in the SAH group than in the non-SAH group (Fig. 2 center) .
Nitroglycerin (0.01-30 M), an activator of guanylate cyclase, 9 elicited concentration-dependent relaxation in both groups of vascular strips. In contrast to the other vasorelaxants, GTN-induced relaxation did not differ significantly between vessels from non-SAH and SAH groups (Fig. 2 right) . A summary of the mean inhibiting concentration (IC 50 ) values of the vasorelaxing agents is presented in Table 1 .
Cyclic Nucleotide Assays
Modifications in vascular responses after SAH could be the result of alterations in the generation of cyclic nucleotide second messengers. In these experiments we examined resting levels of cyclic nucleotides and changes in levels of cyclic nucleotide in response to activation with the signaling molecules in vessels from non-SAH and SAH animals.
Effects of CGRP and Forskolin on cAMP Levels. Resting levels of cAMP did not differ between vessels from non-SAH and SAH animals. The effects of CGRP (1-100 nM) and forskolin (1-100 nM) on cAMP synthesis were examined by treating vessels with a single concentration of these compounds for 3 minutes. Both CGRP and forskolin increased the cellular concentration of cAMP in a concentration-dependent manner (Fig. 3 ). There were no significant differences between non-SAH and SAH groups in their responses to CGRP or forskolin. When compared at the same concentrations (10 and 100 nM), production of cAMP was significantly higher in the forskolin-treated groups than in the CGRP-treated groups of vessels.
Effects of CGRP and GTN on cGMP Levels. Resting levels of cGMP were reduced in SAH vessels (Fig. 4) . In general, CGRP exerted no significant effect on the cGMP levels in vessels from non-SAH or SAH animals. At a concentration of 1 nM, CGRP elicited a slight, but significant, increase in cGMP levels in SAH vessels; however, this was the only case in which CGRP significantly modified cGMP levels (Fig. 4 upper) . In contrast, GTN (10 M) elicited significant increases in cGMP levels in vessels from both groups of animals (Fig. 4 lower) . No significant differences in the magnitude of GTN-induced cGMP generation were observed between vessels from non-SAH and SAH animals. 
Discussion
Functional modification of cerebrovascular messenger systems after SAH has attracted increasing attention. The interest in this issue derives from three basic facts: 1) cerebral vasospasm is the most critical clinical complication that occurs after SAH; 2) the mechanism for vasospasm remains controversial; and 3) an adequate therapeutic treatment for ameliorating the angiographic manifestations of cerebral vasospasm is not available in the clinic. A clear characterization of the functional roles of first and second messengers in the cerebrovasculature is essential for understanding the pathophysiology of cerebral vasospasm after SAH. Several recent studies have evaluated the role of the CGRP signaling system following SAH. The levels of CGRP-like immunoreactivity are reduced after SAH but eventually recover. 3, 18 The functional impact of reduced levels of immunoreactivity may be that less peptide is available for release or that more CGRP is released continuously during vasospasm. The impact of SAH on the functional sensitivity of the CGRP system has also been a topic of investigation. Edvinsson and colleagues 2 have presented evidence that CGRPinduced relaxation is enhanced slightly during peak vasospasm in a rat model of SAH. In contrast, Nozaki, et al., 19 have shown that the relaxant effects of CGRP are attenuated during peak vasospasm in a canine model of SAH. The results of the present study are in accord with the observations of Nozaki, et al. 19 In a rabbit model of SAH, CGRP-induced vasorelaxation was attenuated during peak vasospasm. Thus, a shift to the right of the doseresponse curve for CGRP was observed during peak vasospasm in both canine and rabbit models. 19 The discrepancy between the current observations and those of Edvinsson and associates 5 could be the result of several experimental variables. One obvious explanation for the divergent outcomes is that different species (rat vs. rabbit) were used in the two studies. This explanation is somewhat unlikely given the findings of Nozaki, et al., 20 in which a decreased responsiveness to CGRP was also observed in dogs. Despite the consistency between observations in the rabbit and dog models of SAH, a speciesspecific difference cannot be ruled out as a possible explanation for the different outcome in the rat studies.
Another potential explanation for the differences between the current study and the study of Edvinsson and colleagues 2 is that the vessels under study were precontracted in a somewhat different manner. Both studies used 5-HT to precontract basilar artery segments. However, different degrees of precontraction were probably obtained in the two studies. As shown in the present study and elsewhere, 15, 23 the contractile response to a given concentration of 5-HT differs significantly between vessels from non-SAH and SAH animals. Consequently, a fixed concentration of 5-HT elicits a greater contractile response in vessels from SAH animals than in vessels from non-SAH animals (Fig. 1) . In their study, Edvinsson and colleagues 2 examined the vasodilator effects of CGRP under conditions in which both groups of vessels were precontracted with 1 M 5-HT. It is therefore likely that CGRP-induced contractions were tested under conditions in which different degrees of pharmacological precontraction had been established in the two groups of vessels. The present study circumvented this complication by first determining the dose-response relationships for 5-HTinduced contractions and then selecting concentrations of 5-HT that elicited precontractions of a similar magnitude in the two groups of vessels. Under these conditions, relaxations induced by CGRP were shown to be attenuated in SAH vessels; this finding is similar to the attenuation of CGRP-induced relaxations observed in canine vessels precontracted with prostaglandin F 2␣ . 19 The mechanism(s) underlying the observed attenuation of CGRP-induced relaxation could theoretically involve modifications in any or all of the steps from receptor occupation to muscle-cell contraction. In the present study we evaluated the possibility that alterations in the generation of cyclic nucleotide second messengers contribute to this effect. The generation of cAMP in response to direct activation of adenylate cyclase by forskolin did not differ between vessels from non-SAH and SAH animals. This finding indicates that the capacity for cAMP production is intact during cerebral vasospasm. Moreover, the relaxant response to forskolin was actually facilitated after SAH. This suggests that a direct change in cAMP-mediated relaxation is not responsible for the attenuation of CGRPinduced vasodilation. Finally, the capacity of CGRP to elevate cAMP levels did not differ significantly between vessels from non-SAH and SAH animals. Together these findings suggest that the reduction of CGRP-induced vasorelaxation is not due to a reduction in the ability of CGRP to stimulate cAMP production or to a general attenuation of cAMP-mediated relaxation responses.
Another second messenger postulated to participate in CGRP-mediated vasodilation is cGMP. 24 The response of the cGMP-generating system to SAH has been investigated previously in some detail. Kim and associates 12, 13 have provided evidence that resting levels of cGMP are reduced during cerebral vasospasm in a canine model of SAH. This is consistent with the reduction in resting levels of cGMP in the rabbit SAH model described in our current report. This reduction in the resting levels of cGMP could reflect an attenuation of the release of endothelium-derived relaxing factor; 16, 17 endothelial injury, which is known to occur after SAH, is consistent with this possibility. Another possible explanation for lower cGMP levels after SAH is that the response of smooth muscle to activation of soluble guanylate cyclase is reduced. Kim and associates 13 have provided evidence indicating that the responsiveness of the cGMP generating system is attenuated during vasospasm. Direct stimulation of cGMP production by nitric oxide was attenuated after SAH in the canine model of SAH. Our present results are not in accord with this aspect of the work by Kim and associates. 12, 13 The production of cGMP in response to treatment with GTN did not differ significantly between vessels from non-SAH and SAH rabbits. Moreover, vasorelaxation elicited by GTN did not differ between vessels from non-SAH and SAH rabbits. These findings indicate that although resting levels of cGMP are reduced in the basilar artery of the SAH rabbit, the capacity to generate cGMP directly and to elicit cGMP-mediated vasorelaxation is relatively intact.
The role of cGMP in vasorelaxation that is elicited by CGRP remains to be clarified in this system. The levels of cGMP in rabbit basilar arteries were not significantly affected by CGRP under most treatment conditions. The general lack of a significant elevation of cGMP levels in vessels treated with CGRP suggests that cGMP is not a crucial intermediary of CGRP-induced vasorelaxation in rabbit basilar arteries.
Conclusions
The evidence presented here indicates that CGRP-induced vasorelaxation is attenuated after SAH. This fundamental modification in a potent vasodilatory system could contribute directly to the spastic constriction of cerebral vessels after SAH. In addition, our findings indicate that modifications in two cyclic nucleotide second messenger systems, that of cAMP and cGMP, are unlikely to be responsible for the alteration in the physiological impact of CGRP. Future studies will be directed toward identifying the mechanisms responsible for attenuating vasodilatory function during cerebral vasospasm.
